DCM
LGND icon

Delpha Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Delpha Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-58
Closed -$5K – 716
2017
Q4 		$5K Buy
+58
New +$5.03K 0.01% 1276

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Delpha Capital Management's LGND Position: Q1 2018 in Review

Delpha Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 58 shares — an estimated $5K sold.

Delpha Capital Management first reported a position in LGND in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

  • Delpha Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 58 Ligand Pharmaceuticals shares in Q1 2018, an estimated $5K.
  • Delpha Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Ligand Pharmaceuticals position peaked at $5K in Q4 2017.
  • 326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.